Despite advancements in engineered heart tissue (EHT), challenges persist in achieving accurate dimensional accuracy of scaffolds and maturing human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), a primary source of functional cardiac cells. Drawing inspiration from cardiac muscle fiber arrangement, a three-dimensional (3D)-printed multi-layered microporous polycaprolactone (PCL) scaffold is created with interlayer angles set at 45° to replicate the precise structure of native cardiac tissue. Compared with the control group and 90° PCL scaffolds, the 45° PCL scaffolds exhibited superior biocompatibility for cell culture and improved hiPSC-CM maturation in calcium handling. RNA sequencing demonstrated that the 45° PCL scaffold promotes the mature phenotype in hiPSC-CMs by upregulating ion channel genes. Using the 45° PCL scaffold, a multi-cellular EHT is successfully constructed, incorporating human cardiomyocytes, endothelial cells, and mesenchymal stem cells. These complex EHTs significantly enhanced hiPSC-CM engraftment in vivo, attenuated ventricular remodeling, and improved cardiac function in mouse myocardial infarction. In summary, the myocardium-specific structured EHT developed in this study represents a promising advancement in cardiovascular regenerative medicine.
3D-Printed Myocardium-Specific Structure Enhances Maturation and Therapeutic Efficacy of Engineered Heart Tissue in Myocardial Infarction.
3D打印心肌特异性结构增强了工程化心脏组织在心肌梗死中的成熟度和治疗效果
阅读:9
作者:Wu Yong, Wang Yaning, Xiao Miao, Zhang Guangming, Zhang Feixiang, Tang Mingliang, Lei Wei, Jiang Ziyun, Li Xiaoyun, Zhang Huiqi, Ren Xiaoyi, Xu Yue, Zhao Xiaotong, Guo Chenxu, Lan Hongbo, Shen Zhenya, Zhang Jianyi, Hu Shijun
| 期刊: | Advanced Science | 影响因子: | 14.100 |
| 时间: | 2025 | 起止号: | 2025 Mar;12(10):e2409871 |
| doi: | 10.1002/advs.202409871 | 研究方向: | 炎症/感染 |
| 疾病类型: | 心肌炎 | ||
特别声明
1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。
2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。
3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。
4、投稿及合作请联系:info@biocloudy.com。
